Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

被引：0
|
作者：
T M Beer
D C Smith
A Hussain
M Alonso
J Wang
M Giurescu
K Roth
Y Wang
机构：
[1] Knight Cancer Institute,
[2] Oregon Health & Science University,undefined
[3] University of Michigan Health System,undefined
[4] University of Maryland Medical Center,undefined
[5] Marlene and Stewart Greenebaum Cancer Center,undefined
[6] Private Hospital of Córdoba,undefined
[7] University of Nebraska Medical Center,undefined
[8] Bayer HealthCare Pharmaceuticals,undefined
[9] Astellas Pharma Global Development,undefined
来源：
British Journal of Cancer | 2012年 / 107卷
关键词：
clinical trial; phase II; epothilones; prednisone; prostatic neoplasms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：808 / 813
页数：5
相关论文
共 50 条
  • [41] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
    Akaza, Hideyuki
    Uemura, Hirotsugu
    Tsukamoto, Taiji
    Ozono, Seiichiro
    Ogawa, Osamu
    Sakai, Hideki
    Oya, Mototsugu
    Namiki, Mikio
    Fukasawa, Satoshi
    Yamaguchi, Akito
    Uemura, Hiroji
    Ohashi, Yasuo
    Maeda, Hideki
    Saito, Atsushi
    Takeda, Kentaro
    Naito, Seiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (04) : 773 - 782
  • [42] Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
    Ning, Yang-Min
    Gulley, James L.
    Arlen, Philip M.
    Woo, Sukyung
    Steinberg, Seth M.
    Wright, John J.
    Parnes, Howard L.
    Trepel, Jane B.
    Lee, Min-Jung
    Kim, Yeong Sang
    Sun, Haihao
    Madan, Ravi A.
    Latham, Lea
    Jones, Elizabeth
    Chen, Clara C.
    Figg, William D.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2070 - 2076
  • [43] Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer
    Madan, Ravi A.
    Karzai, Fatima H.
    Ning, Yang-Min
    Adesunloye, Bamidele A.
    Huang, Xuan
    Harold, Nancy
    Couvillon, Anna
    Chun, Guinevere
    Cordes, Lisa
    Sissung, Tristan
    Beedie, Shaunna L.
    Dawson, Nancy A.
    Theoret, Marc R.
    McLeod, David G.
    Rosner, Inger
    Trepel, Jane B.
    Lee, Min-Jung
    Tomita, Yusuke
    Lee, Sunmin
    Chen, Clara
    Steinberg, Seth M.
    Arlen, Philip M.
    Gulley, James L.
    Figg, William D.
    Dahut, William L.
    BJU INTERNATIONAL, 2016, 118 (04) : 590 - 597
  • [44] Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer
    Passildas-Jahanmohan, Judith
    Eymard, Jean-Christophe
    Pouget, Melanie
    Kwiatkowski, Fabrice
    Van Praagh, Isabelle
    Savareux, Laurent
    Atger, Marc
    Durando, Xavier
    Abrial, Catherine
    Richard, Damien
    Ginzac Couve, Angeline
    Thivat, Emilie
    Monange, Brigitte
    Chollet, Philippe
    Mahammedi, Hakim
    CANCER MEDICINE, 2021, 10 (07): : 2332 - 2340
  • [45] Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF
    Aggarwal, Rahul R.
    Beer, Tomasz M.
    Weinberg, Vivian K.
    Higano, Celestia
    Taplin, Mary-Ellen
    Ryan, Charles J.
    Lin, Amy M.
    Alumkal, Joshi
    Graff, Julie N.
    Nordquist, Luke T.
    Herrera, Isheen
    Small, Eric J.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (03) : E191 - E198
  • [46] Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
    Ryan, Charles J.
    Rosenthal, Mark
    Ng, Siobhan
    Alumkal, Joshi
    Picus, Joel
    Gravis, Gwenaelle
    Fizazi, Karim
    Forget, Frederic
    Machiels, Jean-Pascal
    Srinivas, Sandy
    Zhu, Min
    Tang, Rui
    Oliner, Kelly S.
    Jiang, Yizhou
    Loh, Elwyn
    Dubey, Sarita
    Gerritsen, Winald R.
    CLINICAL CANCER RESEARCH, 2013, 19 (01) : 215 - 224
  • [47] Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Hotte, Sebastien J.
    Yu, Evan Y.
    Tu, Dongsheng
    Eigl, Bernhard J.
    Tannock, Ian
    Saad, Fred
    North, Scott
    Powers, Jean
    Gleave, Martin E.
    Eisenhauer, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : 4247 - 4254
  • [48] A phase II study of abiraterone acetate plus prednisone in patients with castration resistant prostate cancer (CRPC) and no prior therapy with ketoconazole
    Ryan, C.
    Harzstark, A.
    Fong, L.
    Lin, A.
    Kilian, C.
    Molina, A.
    Small, E. J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 81 - 81
  • [49] Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer
    Rushworth, Linda K.
    Loveridge, Carolyn
    Salji, Mark
    MacLeod, Martin
    Mui, Ernest
    Sumpton, David
    Neilson, Matthew
    Hedley, Ann
    Alexander, Laura
    McCartney, Elaine
    Patel, Rachana
    Wallace, Jan
    Delles, Christian
    Jones, Rob
    Leung, Hing Y.
    BJU INTERNATIONAL, 2023, 131 (02) : 236 - 243
  • [50] Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel
    Droz, Jean-Pierre
    Medioni, Jaques
    Chevreau, Christine
    De Mont-Serrat, Helene
    Merger, Michael
    Stopfer, Peter
    Kaiser, Rolf
    Oudard, Stephane
    ANTI-CANCER DRUGS, 2014, 25 (09) : 1081 - 1088
12345